Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01164735 · ClinicalTrials.gov registry record
Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
A clinical trial of Recurrent Uterine Corpus Carcinoma and Stage III Uterine Corpus Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- 169
- Enrollment target
- 1
- Study location
NCT01164735 is a study of Recurrent Uterine Corpus Carcinoma and Stage III Uterine Corpus Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 169 participants, below the 633-participant average among 7 other Recurrent Uterine Corpus Carcinoma trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01164735, a study of Recurrent Uterine Corpus Carcinoma and Stage III Uterine Corpus Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- 169 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying biomarkers in tissue samples from patients with stage III, stage IV, or recurrent endometrial cancer. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
Study Locations (1)
Pennsylvania
- Gynecologic Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2010-01 |
| Est. Completion | 2018-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01164735
The ClinicalTrials.gov registry entry for NCT01164735 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 633-participant average among 7 other Recurrent Uterine Corpus Carcinoma trials with a reported enrollment target (73% lower). The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Recurrent Uterine Corpus Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Laboratory Biomarker Analysis is the first listed.
NCT01164735 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01164735 about?
NCT01164735 is a clinical study titled "Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer". This research study is studying biomarkers in tissue samples from patients with stage III, stage IV, or recurrent endometrial cancer. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and i...
What is the current status of trial NCT01164735?
This trial is currently completed. The enrollment target is 169 participants. The study started on 2010-01. Estimated completion is 2018-01.
What conditions does trial NCT01164735 study?
This clinical trial studies the following conditions: Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer.
What interventions are being tested in trial NCT01164735?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT01164735?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01164735 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Uterine Corpus Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
COMPLETED · Phase 2
-
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
COMPLETED · Phase 2
-
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
COMPLETED · Phase 2
-
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
COMPLETED · Phase 3
-
Prognostic Biomarkers in Patients With Endometrial Cancer
COMPLETED
Explore more on PlainTrial
Recurrent Uterine Corpus Carcinoma
All registered trials for this condition
Stage III Uterine Corpus Cancer
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.